A Phase 2 Study of Neoadjuvant Docetaxel, Oxaliplatin, S-1 in Patients With Unresectable Locally Advanced or Distant Metastasis Limited to Lymph Node Gastric Cancer

Gastric cancer is the fifth most common carcinoma in the world, and cancer-related deaths rank third. It is one of the main causes of death from cancer in Korea. The cure method for gastric cancer is radical resection, but in most patients, radical resection is impossible due to local infiltration or peripheral organ or distant metastasis. Many assisted chemotherapy has been studied to improve survival rate, and in East Asia, assisted chemotherapy after complete D2 resection is the standard treatment. In the West, on the other hand, preoperative chemotherapy and postoperative assisted chemothe

Trial Details

NCT ID
NCT05184803
Phase
PHASE2
Sponsor
Asan Medical Center
Status
RECRUITING
Cancer Type
Gastric Cancer
Interventions
  • Docetaxel injection, oxaliplatin, S-1
Locations (sample)
  • Seoul, Seoul, South Korea|37.566,126.9784

Key Eligibility Criteria

  • Histologically or cytologically proven metastatic gastric adenocarcinoma patients
  • As a patient who has been proven by CT to have invasion of surrounding organs (T4) according to the 8th edition of the American Joint Commission (A…
  • Over 18 years old.
  • Patients with a life expectancy of at least 3 months.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastric Cancer Trials on Trialify →